GlassScriptPhysician profile
Julia K Maness
NPI 1154427904
$1,091.51
in general payments reported to CMS, 2019-2025
24 companies · $260 in 2025
The $260 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $213 · 2022: $76.31 · 2023: $257 · 2024: $285 · 2025: $260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $802.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $802.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $175.00 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $100.10 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $80.06 | 2021-2025 | Xifaxan, Trulance |
| Dexcom, INC. | $74.03 | 2024-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.16 | 2021-2025 | Jardiance |
| Lilly USA, LLC | $61.84 | 2021-2025 | Jardiance |
| Novo Nordisk INC | $58.81 | 2022-2024 | Rybelsus, Ozempic, Wegovy |
| Phathom Pharmaceuticals, INC. | $52.29 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $49.12 | 2021-2025 | Capvaxive |
| Otsuka America Pharmaceutical, INC. | $47.54 | 2023 | Rexulti |
| Amgen INC. | $44.17 | 2024-2025 | Evenity, Prolia |
| Abbott Laboratories | $41.90 | 2023-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Alexion Pharmaceuticals, INC. | $33.12 | 2021 | |
| Exact Sciences Corporation | $30.38 | 2024-2025 | Cologuard Collection Kit |
| Harmony Biosciences LLC | $23.95 | 2023 | Wakix |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $20.80 | 2024 | Crysvita |
| Inogen, INC. | $20.53 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Bausch Health US, LLC | $20.42 | 2021 | |
| Insulet Corporation | $19.59 | 2023 | Omnipod |
| Ferring Pharmaceuticals INC. | $18.54 | 2024 | Rebyota |
| Lundbeck LLC | $16.52 | 2024 | Rexulti |
| Sanofi-Aventis U.S. LLC | $14.84 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.94 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $11.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Maness listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.